| pubmed-article:16028332 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16028332 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
| pubmed-article:16028332 | lifeskim:mentions | umls-concept:C0805586 | lld:lifeskim |
| pubmed-article:16028332 | lifeskim:mentions | umls-concept:C2587213 | lld:lifeskim |
| pubmed-article:16028332 | lifeskim:mentions | umls-concept:C0034866 | lld:lifeskim |
| pubmed-article:16028332 | lifeskim:mentions | umls-concept:C0348080 | lld:lifeskim |
| pubmed-article:16028332 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:16028332 | pubmed:dateCreated | 2005-7-19 | lld:pubmed |
| pubmed-article:16028332 | pubmed:abstractText | Case studies and controlled clinical trials indicate that hypnotic analgesia can effectively reduce pain in patients with a number of different chronic pain conditions. However, because none of the studies published to date have included a credible control condition that adequately controls for expectancy effects, at this point we cannot conclude that hypnotic-analgesia treatment has a specific effect on chronic pain beyond that that might be produced by a credible placebo intervention. This paper (a) describes the types of control conditions that have been, or might be, used in clinical trials of hypnotic analgesia for chronic pain; (b) reviews their strengths and weaknesses; and (c) concludes with specific recommendations that investigators should consider when designing clinical trials of hypnotic analgesia. | lld:pubmed |
| pubmed-article:16028332 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16028332 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16028332 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16028332 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16028332 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16028332 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:16028332 | pubmed:issn | 0020-7144 | lld:pubmed |
| pubmed-article:16028332 | pubmed:author | pubmed-author:JensenMark... | lld:pubmed |
| pubmed-article:16028332 | pubmed:author | pubmed-author:PattersonDavi... | lld:pubmed |
| pubmed-article:16028332 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16028332 | pubmed:volume | 53 | lld:pubmed |
| pubmed-article:16028332 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16028332 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16028332 | pubmed:pagination | 170-97 | lld:pubmed |
| pubmed-article:16028332 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:16028332 | pubmed:meshHeading | pubmed-meshheading:16028332... | lld:pubmed |
| pubmed-article:16028332 | pubmed:meshHeading | pubmed-meshheading:16028332... | lld:pubmed |
| pubmed-article:16028332 | pubmed:meshHeading | pubmed-meshheading:16028332... | lld:pubmed |
| pubmed-article:16028332 | pubmed:meshHeading | pubmed-meshheading:16028332... | lld:pubmed |
| pubmed-article:16028332 | pubmed:meshHeading | pubmed-meshheading:16028332... | lld:pubmed |
| pubmed-article:16028332 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:16028332 | pubmed:articleTitle | Control conditions in hypnotic-analgesia clinical trials: challenges and recommendations. | lld:pubmed |
| pubmed-article:16028332 | pubmed:affiliation | Department of Rehabilitation Medicine, Box 356490, University of Washington, Seattle, WA 98195-6490, USA. mjensen@u.washington.edu | lld:pubmed |
| pubmed-article:16028332 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16028332 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:16028332 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:16028332 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16028332 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16028332 | lld:pubmed |
